Form 4: Forte Biosciences CFO Reports RSU Vesting & Share Sale

Forte Biosciences' Chief Financial Officer, Antony A. Riley, reported the exercise of restricted stock units and subsequent disposition of shares for tax obligations.

Summary

• Antony A. Riley, Chief Financial Officer of Forte Biosciences, Inc. (FBRX), reported transactions involving the company's common stock and restricted stock units (RSUs).
• On October 1, 2025, Riley acquired 375 shares of common stock upon the vesting of RSUs at a price of $0.
• Concurrently, 134 shares of common stock were disposed of at a price of $14.52 per share to cover tax liabilities associated with the RSU vesting.
• Following these transactions, Riley directly beneficially owns 31,840 shares of common stock.
• Riley also directly beneficially owns 1,875 restricted stock units.
• The RSUs vest in installments, with 1/16th vesting on each Quarterly Vesting Date (January 1, April 1, July 1, and October 1) on or immediately following February 1, 2023, contingent on continued service.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the vesting of restricted stock units and a subsequent tax-related share disposition. This is a standard event for executive compensation and does not indicate any significant positive or negative operational or financial developments for the company.

Positives

• The vesting of 375 restricted stock units indicates the fulfillment of compensation agreements and continued service by the Chief Financial Officer.
• The acquisition of shares at a $0 price upon RSU vesting represents a non-cash gain for the insider.

Negatives

• The disposition of 134 shares of common stock at $14.52 per share reduces the direct beneficial ownership of the Chief Financial Officer by that amount, which is a common practice for tax withholding but still represents a reduction in holdings.

Future Outlook

The remaining 1,875 Restricted Stock Units held by the Chief Financial Officer are subject to a vesting schedule, with 1/16th of the award vesting on each Quarterly Vesting Date (January 1, April 1, July 1, and October 1) on or immediately following February 1, 2023, provided the reporting person continues to be a Service Provider.

Industry Context

This filing is a routine insider transaction report and does not provide information relevant to broader industry trends or competitive landscape analysis. It reflects standard equity compensation practices for executives.

Stakeholder Impact

• Shareholders: Minimal direct impact. The disposition of shares for tax purposes is a routine event and does not signal a change in the company's fundamentals or the insider's long-term view. The increase in outstanding shares from RSU vesting is negligible.
• Employees: Reflects standard equity compensation practices for executives, which can be a positive for employee morale regarding compensation structure.

Next Steps

• Continued vesting of the remaining 1,875 Restricted Stock Units on future Quarterly Vesting Dates (January 1, April 1, July 1, October 1), subject to the CFO's continued service.

Key Dates

Keywords

Forte Biosciences, FBRX, Antony A. Riley, CFO, Insider Trading, Form 4, Restricted Stock Units, RSU Vesting, Share Disposition, Equity Compensation, SEC Filing